Last reviewed · How we verify
WD-1603
At a glance
| Generic name | WD-1603 |
|---|---|
| Sponsor | Hong Kong WD Pharmaceutical Co., Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants (PHASE1)
- Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions (PHASE1)
- A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease (PHASE2)
- PK Study of WD-1603 in Healthy Subjects (PHASE1)
- A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions (PHASE1)
- WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects (PHASE1)
- WD-1603 PK Study in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |